PSA (KLK3, a widely used clinical biomarker for PCa) was shown to dramatically boost the expression of KLKB1 (average intensity = 16.05) serine proteases that demonstrate unregulated expression in PCa. This evidence concerns the gene KLKB1 and posterior cortical atrophy.